Associated tags: MDD, DSM-IV codes, TMS, Depression, Neuroscience, FDA, Mental health, Tic disorder, Transcranial magnetic stimulation, Quality of life, Patient, STIM, Pharmaceutical industry, Neuronetics
Locations: JAPAN, MT, CANADA, MICHIGAN, AETNA, THE RETREAT, MALVERN, PA, US, CENTRAL, UNITED STATES
MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 18,000 shares of the Company’s common stock (RSUs) to four new non-executive employees.
Key Points:
- MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 18,000 shares of the Company’s common stock (RSUs) to four new non-executive employees.
- In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
- Each of the RSU grants vests ratably in three equal installments on the first, second and third anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date.
- The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
Retrieved on:
Tuesday, October 24, 2023
The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Key Points:
- The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
- The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a2ncdxuo.
- To listen to the conference call on your telephone, participants may register for the call here .
- While it is not required, it is recommended you join 10 minutes prior to the event start.
TMS,
STIM,
Neuronetics,
Radiology,
Transcranial magnetic stimulation,
Columbia University,
DSM-IV codes,
Clinical research,
FDA,
SVP,
Marketing,
PHQ-9,
Depression,
MDD,
Patient,
Quality of life,
Pharmaceutical industry,
Nursing,
Neuromodulation,
Psychiatry The data reveal a robust association between the number of treatment sessions received and improved depression outcomes, providing actionable evidence for clinicians prescribing transcranial magnetic stimulation (TMS) therapy to treat major depressive disorder (MDD).
Key Points:
- The data reveal a robust association between the number of treatment sessions received and improved depression outcomes, providing actionable evidence for clinicians prescribing transcranial magnetic stimulation (TMS) therapy to treat major depressive disorder (MDD).
- Historically, TMS therapy is discontinued by either the patient or the practitioner at various points of treatment, but the findings published in Brain Stimulation demonstrate that stopping treatment before 36 sessions is associated with significantly reduced treatment effectiveness.
- “These findings underscore the importance of patients completing the full prescribed treatment course to achieve the best outcomes,” stated Cory Anderson, SVP of R&D and Clinical.
- The NeuroStar Outcomes Registry is providing a wealth of data on real-world outcomes, and substantially shaping our understanding of clinical best practices for TMS therapy in MDD.”
The NeuroStar Outcomes Registry is the world’s largest registry of depression outcomes.
“We are pleased to have successfully drawn down the remaining capital as part of our credit facility with SLR, which further bolsters our balance sheet in a non-dilutive manner and will support the ongoing execution of our strategy,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics.
Key Points:
- “We are pleased to have successfully drawn down the remaining capital as part of our credit facility with SLR, which further bolsters our balance sheet in a non-dilutive manner and will support the ongoing execution of our strategy,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics.
- “Given the current challenging equity and debt capital markets environment, we felt it was prudent to strengthen our balance sheet in a cost-effective manner.
- This facility includes three tranches of term loans, consisting of a “Term A Loan” of $35.0 million, a “Term B Loan” of $2.5 million, and a “Term C Loan” of $22.5 million.
- The Company has drawn down all $60.0 million available as part of this credit facility and the maturity date of the $60 million facility is now set for March 29, 2028.
Retrieved on:
Tuesday, September 12, 2023
Male,
Depression,
Freedom,
Senior,
Suicide,
Marketing,
National Suicide Prevention Week,
Quality of life,
STIM,
What Could Possibly Go Wrong? (book),
Patient,
Family,
Pharmaceutical industry,
Neuronetics “Depression can be isolating, and we want people suffering from it to realize they are not alone.
Key Points:
- “Depression can be isolating, and we want people suffering from it to realize they are not alone.
- These ambassadors will share their own stories and connect with potential patients to increase awareness around NeuroStar treatment and foster a sense of community.
- During Suicide Prevention Month and beyond, individuals enduring the difficulties of depression will find solace in stories of resilience and recovery, like Damon's.
- The stories of NeuroStar ambassadors will be amplified through strategic efforts across social, digital, and earned media.
Clinician Administered PTSD Scale,
Catholic Communication Campaign,
Depression,
Senior,
Professional,
AMCP,
Marketing,
Quality of life,
STIM,
Neuronetics,
Patient,
Gold,
Digital,
Nursing MALVERN, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is thrilled to announce NeuroStar Advanced Therapy’s “Tap Into A New Possibility for Depression” campaign has been awarded Gold by the 2023 dotCOMM Awards in the category of Digital Marketing & Communication Campaigns.
Key Points:
- MALVERN, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is thrilled to announce NeuroStar Advanced Therapy’s “Tap Into A New Possibility for Depression” campaign has been awarded Gold by the 2023 dotCOMM Awards in the category of Digital Marketing & Communication Campaigns.
- “This award is a recognition of our efforts to not only raise awareness about NeuroStar, but to also educate patients and guide their path to treatment.
- Neuronetics’ marketing team, with creative partner Hyperquake, has recently expanded the “Tap Into A New Possibility for Depression” campaign, shifting the spotlight onto the inspirational journeys of numerous patients who triumphed over depression and found their way to recovery with the help of NeuroStar Advanced Therapy.
- For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .
Communication,
Marketing,
TMS,
EMR,
Quality of life,
SMS,
STIM,
Medical director,
Patient,
Growth,
Health,
Neuronetics,
Demographic and Health Surveys,
Nursing,
Psychiatry The update introduces a range of automated features to improve communication between providers and their existing and prospective patients, while also saving practices time in recording and documenting results.
Key Points:
- The update introduces a range of automated features to improve communication between providers and their existing and prospective patients, while also saving practices time in recording and documenting results.
- This marks the second significant upgrade to the platform this year.
- To facilitate seamless utilization of the automated SMS texting and email features, TrakStar makes it convenient to update patient contact details in one location.
- Additionally, a new export feature effortlessly shares or saves patient survey results if needed by insurance providers or for storing in an electronic medical record (EMR) system.
Depression,
OCD,
Aetna,
TMS,
Telephone,
BCBS,
Policy,
Food and Drug Administration,
Blue Cross Blue Shield Association,
EBITDA,
DSM-IV codes,
MDD,
Patient,
Webcast,
Neuronetics,
Mental health,
Food,
Cryptocurrency,
Video game,
Pharmaceutical industry,
Beauty salon In the second quarter of 2023, U.S. treatment session revenue per active site was approximately $11,392 compared to approximately $11,280 in the second quarter of 2022.
Key Points:
- In the second quarter of 2023, U.S. treatment session revenue per active site was approximately $11,392 compared to approximately $11,280 in the second quarter of 2022.
- Gross margin for the second quarter of 2023 was 72.5%, a decrease of approximately 280 basis points from the second quarter of 2022 gross margin of 75.3%.
- Operating expenses during the second quarter of 2023 were $20.1 million, a decrease of $2.0 million, or 9%, compared to $22.1 million in the second quarter of 2022.
- EBITDA for the second quarter of 2023 was $(3.3) million as compared to the second quarter of 2022 EBITDA of $(9.1) million.
MALVERN, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 27,000 shares of the Company’s common stock (RSUs) to five new non-executive employees.
Key Points:
- MALVERN, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 27,000 shares of the Company’s common stock (RSUs) to five new non-executive employees.
- In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
- Each of the RSU grants vests ratably in three equal installments on the first, second and third anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date.
- The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2023 financial and operating results prior to market open on Tuesday, August 8th, 2023.
Key Points:
- MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2023 financial and operating results prior to market open on Tuesday, August 8th, 2023.
- The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
- The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/papp9yri .
- To listen to the conference call on your telephone, participants may register for the call here .
